Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14912005 | 0.82 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL2186411 | 0.73 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL873444 | 0.73 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL51254 | 0.73 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL1957441 | 0.73 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL5152191 | 0.73 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL8485 | 0.72 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL16572184 | 0.71 | GBA1 (0.52) | TAAR1 | |
| Methane SCHEMBL28820455 | 0.71 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL183865 | 0.70 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113968824-A | 2,3, 5-trisubstituted pyrazine compound and preparation method and application thereof | 郑州大学 | 2022-01-25 | — | — | CN | claimed |
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | MERCK PATENT GMBH (DE) | 2019-05-21 | — | — | US | claimed |
| EP-2970258-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2018-04-18 | — | — | EP | claimed |
| US-9657034-B2 | Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors | AbbVie Deuschland GmbH & Co. KG (DE) | 2017-05-23 | — | — | US | claimed |
| EP-3151829-A1 | NOVEL SESQUITERPENE DERIVATIVES AND THEIR USE IN INFLAMMATION AND CANCER TREATMENT | Academia Sinica (TW) | 2017-04-12 | — | — | EP | claimed |
| EP-2776418-B1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-01-04 | — | — | EP | claimed |
| US-9475808-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | claimed |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-05-19 | — | — | US | claimed |
| US-9273068-B2 | Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-01 | — | — | US | claimed |
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | claimed |
| WO-2002083691-A1 | NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | claimed |
| EP-1165505-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-01-02 | — | — | EP | claimed |
| EP-1140814-A2 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000059880-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-10-12 | — | — | WO | claimed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | claimed |
| WO-2000039081-A2 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-07-06 | — | — | WO | claimed |
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999001128-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| US-5710158-A | INHIBITORS OF PROTEIN TYROSINE KINASE AND EPIDERMAL GROWTH FACTOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | claimed |
| US-5245039-A | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE POLYSUBSTITUTED 1,4-DIHYDROPYRIDINES | BOEHRINGER MANNHEIM ITALIA (IT) | 1993-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | SLC6A2 1970/4885SLC6A4 1479/4885SLC6A3 1046/4885 |
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | PSMB7, PSMA7, PSMB11 | SLC6A2 4149/4885SLC6A4 4747/4885SLC6A3 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.